Synlogic Q2 2026: Cash Runway Through 2027, Merger with Caldera, and Warrant Repricing
SYBX has more than doubled off its 52-week low of $0.54 on light trading volume (0.1× avg).
Summary
Synlogic reported Q2 2026 results with $13.2M in cash, sufficient for 12+ months. The company disclosed a pending merger with Caldera Therapeutics that would leave current shareholders with only 2.3% of the combined entity, and a warrant repricing to $0.70. Material weakness in internal controls remains.
Key Events · Earnings and Guidance · SYBX
-
Cash Runway Extended
Cash and cash equivalents of $13.2 million as of June 30, 2026, down from $14.7 million at year-end 2025. Management states this is sufficient to fund operations at current levels for at least 12 months from the filing date.
-
Merger with Caldera Therapeutics
On July 28, 2026, Synlogic entered into a definitive merger agreement with Caldera Therapeutics. Upon closing, pre-merger Synlogic equity holders are expected to own approximately 2.3% of the combined company, with Caldera holders owning 62.8% and new investors 34.9% (assuming a $278 million concurrent financing). The combined company will focus on Caldera's CLD-423 for inflammatory bowel disease.
-
Warrant Repricing
On July 27, 2026, Synlogic amended outstanding warrants to reduce the exercise price from $3.408 to $0.70 per share and removed the holders' right to require cash redemption upon a fundamental transaction. The warrants cover 7,394,363 shares.
-
Material Weakness Persists
Management's evaluation concluded that disclosure controls and procedures were not effective as of June 30, 2026, due to a previously identified material weakness in internal control over financial reporting that remains unremediated.
Analysis · SYBX · Life Sciences
Synlogic's Q2 2026 report reveals a cash balance of $13.2 million, which management says funds operations for at least 12 months. The company remains a shell with no revenue, but the big news is the subsequent merger agreement with Caldera Therapeutics, which would give current Synlogic shareholders just 2.3% of the combined company. The warrant exercise price was also slashed to $0.70, removing a cash redemption feature. A material weakness in internal controls persists, and disclosure controls are ineffective. The merger, if completed, fundamentally changes the investment thesis — Synlogic becomes a tiny piece of a new biotech focused on inflammatory bowel disease.
At the time of this filing, SYBX was trading at $1.18 on OTC in the Life Sciences sector, with a market capitalization of approximately $14.5M. The 52-week trading range was $0.54 to $1.96. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.